What does an earnings surprise mean?

An earnings surprise is the difference between a company's reported EPS or revenue and the analysts' consensus estimate. A positive surprise means results exceeded expectations, while a negative surprise means results fell short.

How can earnings reports affect CHRS stock?

Earnings reports can increase volatility in CHRS stock, especially when reported EPS, revenue or company guidance differs from market expectations. An earnings beat does not always lead to a price increase, as investors also consider the outlook, valuation and broader market conditions.

Coherus BioSciences Inc Earnings Dates & Reports

This page offers detailed Coherus BioSciences Inc earnings data including the latest Coherus BioSciences Inc earnings report, the upcoming Coherus BioSciences Inc earnings date, historical data and Coherus BioSciences Inc earnings call news.

CHRS Latest Quarter’s Earnings

Announce Date8/5/2026

EPS Actual (USD)-0.13

Revenue Actual (USD)14.31M

CHRS Upcoming Quarter's Earnings

Announce Date--

EPS Forecast (USD)--

Revenue Forecast (USD)--

CHRS FY2025 Earnings

EPS (YoY)1.43476.39%

Revenue (YoY)42.17M59.81%

Coherus BioSciences Inc (CHRS) Earnings History

Release Date	Period End	EPS/Forecast	Revenue/Forecast	EPS Surprise %	Revenue Surprise %
8/5/2026	06/2026	-0.13/-0.20	14.31M/14.40M	33.37%	-0.65%
5/11/2026	03/2026	-0.28/-0.27	12.31M/14.34M	-2.80%	-14.17%
3/9/2026	12/2025	-0.31/-0.34	12.75M/13.94M	8.94%	-8.58%
11/6/2025	09/2025	-0.31/-0.33	11.57M/13.41M	5.94%	-13.73%
8/7/2025	06/2025	2.57/-0.30	10.25M/10.13M	964.68%	1.17%
5/12/2025	03/2025	-0.49/-0.23	7.60M/54.66M	-110.46%	-86.10%
3/10/2025	12/2024	-0.44/-0.13	54.14M/47.27M	-234.25%	14.54%
11/6/2024	09/2024	-0.09/-0.13	70.77M/59.23M	30.01%	19.49%

Coherus BioSciences Inc Earnings News

Coherus Oncology Q2 2026 Earnings: LOQTORZI Growth Narrows the Loss

Coherus Oncology (CHRS) reported Q2 2026 net revenue of $14.3 million, up about 40% from $10.3 million, while LOQTORZI revenue rose 37% to $13.6 million. The continuing-operations net loss narrowed to $33.3 million, or $0.22 per diluted share, from $44.9 million, or $0.39. Lower R&D and SG&A expenses supported the improvement, but quarterly operating cash use increased to $62.1 million and cash, equivalents and marketable securities fell to $105.3 million at June 30. Pipeline data disclosures are expected in the second half of 2026.

TradingKeyWed, Aug 5

Coherus BioSciences Inc